-
Product Insights
NewCoronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024
Empower your strategies with our Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through...
-
Product Insights
NewArteriosclerosis – Drugs In Development, 2024
Empower your strategies with our Arteriosclerosis – Drugs In Development, 2024 report and make more profitable business decisions. Arteriosclerosis refers to the thickening and hardening of arteries due to plaque buildup, limiting blood flow. Atherosclerosis, a common form, involves cholesterol and other substances accumulating in arterial walls, narrowing them. This condition heightens the risk of heart disease, stroke, and peripheral artery disease. Factors like high blood pressure, cholesterol, smoking, diabetes, and obesity contribute. Management involves lifestyle changes—such as a healthy diet...
-
Product Insights
NewAtherosclerosis – Drugs In Development, 2024
Empower your strategies with our Atherosclerosis – Drugs In Development, 2024 report and make more profitable business decisions. Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive buildup of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina); pain in the leg, arm, and anywhere else that an artery is blocked; shortness of breath;...
-
Sector Analysis
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...